price may usd
revenu usdm
mix commentari ep
buy rate agil reflect view compani opportun
growth margin expans capit deploy peer result
agil lower core revenu growth outlook maintain
adjust ep guid mix implic thesi
thing like
 acg growth remain healthi april end quarter acg segment
growth outpac demand broad-bas across region
includ mid-teen growth china manag expect healthi
perform continu fy maintain high-singl digit
organ growth outlook
management share repo although quarterli result pretti like
agil maintain adjust ep guidanc rang
despit lower core growth outlook revenu forecast
basi point basi point respect mid-point
reflect mix disciplin expens manag capit deploy
inde agil intend repurchas share fy
thing cautiou
 organ sale growth miss organ sale growth came light
forecast consensu under-perform
driven primarili lsag busi declin y/i vs
forecast dgg busi also miss forecast acg
busi outperform vs dbe manag attribut
lsag weak slow instrument order china especi
food well gener global slowdown demand among small
lower organ sale growth outlook china small mol
headwind agil revis sale growth outlook
 previous basi point mid-point downward
revis reflect softer fy outlook lsag busi
specif manag dampen outlook reflect headwind
china relat food pharma end market well headwind
broader pharma small molecul market agil outlook
deutsch bank seek busi compani cover research report thu investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis disclosur analyst certif locat
distribut gmt
acg dgg busi remain unchang
 china growth headwind persist recoveri expect
china grew recoveri food market yet materi
follow govern food ministri reorgan
govern bulk tender program advers
expect impact small molecul pharma custom manag
bake recoveri lower growth expect
high-singl digit previous posit side agil expect
continu strength acg busi perform well
 pharma biotech growth deceler meaning pharma
biotech growth deceler prior quarter
manag attribut weak china pharma mention
well global soft instrument sale among small molecul
custom delay instrument replac purchas inde
manag note larg pharma account europ
delay purchas decis addit agil lower growth
expect global biopharma mid-singl digit high-singl digit
expect previous posit side agil note demand
trend among larg molecul custom remain healthi
agil pharma biotech busi
lower pt
lower price target reflect lower group multipl
lower ebitda forecast well roll forward valuat framework
price target agil reflect enterpris valu use project level debt
cash ebitda ex option estim ttm end
multipl in-lin life scienc tool peer group median ev/ftm ebit-
period end incom expens expens incom share share ep dilut per sale oper cash flowoper cash cash revenu
period end equival st current equip intang asset cash lt sharehold equityaccount matur lt current liabil sh equiti minor may
price current end previou trade session unless otherwis indic sourc local exchang via reuter bloomberg vendor
inform sourc deutsch bank subject compani sourc disclosur pertain recommend estim made secur primari
subject research pleas see recent publish compani report visit global disclosur look-up page websit http //research db com/research/disclosures/
companysearch asid within report import risk conflict disclosur also found investor
strongli encourag review inform invest
import disclosur requir regul
disclosur mark asterisk may also requir least one jurisdict addit unit state see
import disclosur requir non-u regul explanatori note
